舒利迭联合胸腺肽肠溶片治疗中重度慢性阻塞性肺疾病疗效观察

Effect of Thymosin Enteric-coated Tablet Combined with Seretide on Lung Function and Immune Function in Patients with Moderate and Severe COPD

目的:探讨舒利迭联合胸腺肽肠溶片治疗中重度慢性阻塞性肺疾病(以下简称慢阻肺)的临床效果,提高慢阻肺的治疗效果。方法:选取2020年4月—2021年12月在上海市嘉定区南翔医院治疗的中重度慢阻肺患者120例,按照随机数字表法将其分为对照组(n=60)和观察组(n=60)。在常规治疗的基础上,给予对照组患者舒利迭治疗;给予观察组患者舒利迭联合胸腺肽肠溶片治疗。比较两组患者肺功能指标、血流动力指标、呼吸困难评分、慢阻肺评估测试(CAT)评分、生活质量、免疫功能及满意度情况。结果:治疗后,观察组患者用力肺活量(FVC)、第1秒钟用力呼气容积(FEV_(1))、第1秒钟用力呼气容积/用力肺活量(FEV_(1)/FVC)、氧分压(PaO_(2))、CD4^(+)水平均高于对照组患者,差异均有统计学意义(t值分别为5.906、4.752、5.616、2.791、12.044,P值均<0.05);二氧化碳分压(PaCO_(2))、呼吸困难评分、CAT评分、生活质量评分各项评分(症状、影响及活动)、CD3+、CD8+水平均低于对照组,差异均有统计学意义(t值分别为13.435、1.983、8.276、8.434、6.033、5.161、5.131、23.878,P值均<0.05);观察组患者总满意度为86.67%,对照组患者总满意度为61.67%,两组比较,差异有统计学意义(χ^(2)=9.786,P<0.05)。结论:舒利迭联合胸腺肽肠溶片可有效改善中重度慢阻肺患者的免疫功能,提高患者肺功能,患者对治疗的满意度高。

OBJECTIVE To explore the effect of thymidin enteric-coated tablets combined with sullidi on pulmonary function and immune function in patients with moderate to severe chronic obstructive pulmonary disease(COPD),in order to reduce the treatment cost and improve the quality of life of patients.METHODS A total of 120 patients with moderate to severe COPD in our hospital from April 2020 to December 2021 were selected as the research objects,and divided into the control group according to the random number table method(n=60)and observation group(n=60).The pulmonary function,hemodynamic index,dyspnea score,COPD assessment test score,quality of life score,immune function and satisfaction were compared between the two groups.RESULTS Post-treatment,in the observation group,forced lung capacity(FVC),1 second forced breath volume(FEV_(1)),1 second forced breath volume(FEV_(1)/FVC),oxygen partial pressure(PaO_(2)),and CD4+levels were all higher than those in the control group,the differences were statistically significant(t=5.906,4.752,5.616,2.791,12.044,respectively,P<0.05).The partial pressure of carbon dioxide(PaCO_(2)),dyspnea score,CAT score,quality of life score(symptoms,effects and activities),CD3+,CD8+levels were lower than the control group,the differences were statistically significant(t=13.435,1.983,8.276,8.434,6.033,5.161,5.131,23.878,respectively,P<0.05).The total patient satisfaction in the observation group was 86.67%,The total patient satisfaction rate in the control group was 61.67%,Comparing the two groups,Statistically significant difference(χ^(2)=9.786,P<0.05).CONCLUSION Thymosin enteric-coated tablet combined with seridine can effectively improve the immune function and lung function of patients with moderate and severe COPD,and can improve the satisfaction of treatment.